Physiomics, which provides solutions to predict the effects of cancer treatment regimens, said it was trading in line with expectations for the year through June. Trading for the current financial year, meanwhile, had 'started well' with a further contract with Bicycle Therapeutics, announced on 30 June, a strong continuing relationship with Merck. 'In addition, the company's investment in additional marketing capability has led to an increased volume of introductory calls with potential new clients, some of which the board hopes will be converted into further projects in the second half of this calendar year,' Physiomics said. Net cash as at 30 June stood at £1.1m, strengthened by a £0.83m share placing in May.
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.